Biomerica, Inc.(BMRA)Earnings, Financials & Key Ratios

BMRA•NASDAQ

$1.75

Price updated Jun 27, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryDevice suppliers, distribution, and services

AboutBiomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Show more

Revenue$5M-1.9%
EBITDA-$5M+21.0%
Net Income-$5M+16.8%
EPS (Diluted)-2.16-500.0%
Gross Margin9.38%-16.9%
EBITDA Margin-89.19%+19.4%
Operating Margin-96.72%+17.7%
Net Margin-93.64%+15.2%
ROE-92.99%-42.4%

BMRA Price & Volume

Biomerica, Inc. (BMRA) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Contraction Threatens Operational Liquidity Runway

Investment Thesis • Updated 2026Q3

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Capital exhaustion and liquidity

Key Thesis Takeaways

Biomerica faces a critical inflection point as its legacy diagnostic business continues to erode, evidenced by a revenue decline to $987.0K in 2026Q3.
The company's strategic pivot toward the InFoods platform remains unproven, with operating margins collapsing to -131.5% and cash reserves dwindling to $1.3 million.
Investors should remain cautious as the firm's inability to achieve positive free cash flow, which reached -$1.3 million in 2026Q3, suggests significant ongoing liquidity risk.

Verdict Logic

the company's net margin of -132.9% and the rapid depletion of cash reserves to $1.3 million indicate a high probability of future capital dilution or liquidity distress.

BMRA Growth Metrics

Biomerica, Inc. (BMRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years0.68%

5 Years-4.52%

3 Years-34.47%

TTM-14.07%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM20.73%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-266.98%

Return on Capital

10 Years-47.61%

5 Years-65.02%

3 Years-74.15%

Last Year-91.28%

Peers Comparison

Key metrics vs top competitors for Biomerica, Inc. (BMRA)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
BMRABiomerica, Inc.Current	$1.75	$5.41M	-0.81	-1.92%	-93.64%	-92.99%	—
CODXCo-Diagnostics, Inc.	$3.06	$3.42M	-0.09	-84.1%	-6753.69%	-164.92%	—
QDELQuidelOrtho Corporation	$13.79	$938.85M	-0.83	-1.89%	-45.57%	-56.31%	—
OSUROraSure Technologies, Inc.	$4.46	$320.97M	-4.74	-38.1%	-61.93%	-15.09%	—
HOLXHologic, Inc.	$76.01	$16.97B	30.53	1.74%	13.18%	11.01%	—
BIOBio-Rad Laboratories, Inc.	$300.79	$8.12B	10.79	0.65%	6.52%	2.4%	—